None listed
Conditions
Interventions
Dietary Supplement : The investigational product in this clinical trial is orally administered once daily (one tablet per dose) with water for 12 weeks. Participants will be randomly assigned to eithe
Sponsors
DERMAPRO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ?Men or women aged 30–60 with visible wrinkles in the test area ?Individuals with a cheek skin hydration level of =48 (Corneometer® value) ?Individuals with a crow’s feet wrinkle grade of =3 (according to DermaPro SOP criteria) (Fig. 2) ?Healthy individuals with no acute or chronic physical diseases, including skin disorders ?Individuals who have been fully informed about the purpose and procedures of the study and have voluntarily signed the consent form ?Individuals who are able to comply with follow-up visits throughout the study period
Exclusion criteria
Exclusion criteria: ? Pregnant, breastfeeding, or planning to become pregnant ? Having irritation or allergies to foods containing ingredients related to cosmetics, pharmaceuticals, or test samples ?Having continuously consumed, within 3 months prior to the start of the study, any health functional foods that may affect the test results (health functional foods containing ingredients notified or approved by the Ministry of Food and Drug Safety: NAG (N-acetylglucosamine), konjac potato extract, spirulina, chlorella, aloe gel, chlorophyll-containing plants, phosphatidylserine, hyaluronic acid, collagen peptides, PME-88 melon extract, elastin peptides, galactooligosaccharide powder, rosemary–grapefruit extract complex, dandelion extract complex, wheat extract, wheat germ extract, perilla leaf extract, pomegranate concentrate powder, pine bark extract complex, hydrangea leaf hot-water extract, rice bran extract, corn germ extract, whey protein lipid extract, lithospermum extract, soybean–barley fermentation complex, probiotics HY7714, fingerroot extract powder, honeybush extract fermented powder, red ginseng, cnidium–cornus fruit mixed extract, etc.) ?Having used topical skin products containing steroids, or having taken oral retinoids/steroids or immunosuppressants within 6 months prior to the start of the study ?Having undergone or planned any procedures on the test area within 3 months prior to the start (chemical peeling, Botox, other skin treatments, etc.) ?Having participated in the same study within the past 3 months ?Having diseases that may influence the study (heart, kidney, liver, thyroid, cerebrovascular diseases, gallbladder diseases, gastrointestinal disorders, gout, etc.) ?Having skin diseases (such as atopic dermatitis) on the test area ?Having chronic wasting diseases (such as asthma, diabetes, hypertension, etc.) ?Having mental illnesses (such as depression, schizophrenia, alcoholism, drug addiction, etc.) ?Taking anti-obesity medications (fat absorption inhibitors, antidepressants, appetite suppressants, etc.), contraceptives or hormonal agents, or diuretics ?Excessive alcohol consumption (= 40 g/day for men, = 20 g/day for women) ?Excessive smoking (= 20 cigarettes/day) ?Having sensitive or hypersensitive skin ?Having skin abnormalities in the test area (such as moles, acne, erythema, telangiectasia, etc.) ?Any other condition deemed by the principal investigator to make study participation difficult
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin Wrinkle (PRIMOS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin Hydration (CORNEOMETER, MOISTUREMETER);Transepidermal Water Loss;Skin Elasticity (CUTOMETER);Skin Brightness, Redness;weight, body fat mass, BMI, body fat percentage, abdominal fat percentage; Adverse Event | — |
Countries
Korea, Republic of
Contacts
Public ContactRyu Ja Hyun
DERMAPRO
Outcome results
None listed